- Home
- BODI vs PSTV Comparison
BODI vs PSTV Comparison
Compare BODI & PSTV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BODI | PSTV |
|---|---|---|
| Founded | 1998 | 1996 |
| Country | United States | United States |
| Employees | 355 | N/A |
| Industry | Industrial Machinery/Components | Medical/Dental Instruments |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 56.8M | 46.4M |
| IPO Year | N/A | 2016 |
Fundamental Metrics
Financial Performance| Metric | BODI | PSTV |
|---|---|---|
| Price | $11.00 | $0.27 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 4 |
| Target Price | ★ $11.00 | $6.75 |
| AVG Volume (30 Days) | 29.6K | ★ 3.9M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 87.61 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $5,213,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $25.37 | $46.30 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $3.38 | $0.16 |
| 52 Week High | $12.66 | $2.08 |
Technical Indicators
Market Signals| Indicator | BODI | PSTV |
|---|---|---|
| Relative Strength Index (RSI) | 63.68 | 39.96 |
| Support Level | $10.18 | $0.26 |
| Resistance Level | $12.66 | $0.32 |
| Average True Range (ATR) | 0.85 | 0.03 |
| MACD | 0.42 | 0.00 |
| Stochastic Oscillator | 85.08 | 7.74 |
Price Performance
Historical ComparisonAbout BODI The Beachbody Company Inc.
The Beachbody Co Inc is a health and wellness platform providing fitness, nutrition and stress-reducing programs to its customers. The product offerings of the company include Digital Subscriptions, Nutritional Products, and Connected Fitness Products. It earns the majority of its revenue from the United States. The company operates and manages its business in one operating segment. Majority of revenue is through Digital.
About PSTV PLUS THERAPEUTICS Inc.
Plus Therapeutics Inc is a clinical-stage pharmaceutical company that focuses on discovering, developing, and delivering complex treatments for patients with cancer and rare diseases. The company is working on a range of potential products, with its main programs targeting recurrent glioblastoma (GBM) and leptomeningeal metastases (LM). One of its key candidates, rhenium (186Re) obisbemeda, is specifically designed to treat central nervous system (CNS) cancers such as GBM, LM, and pediatric brain cancers (PBC).